Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH-2007-2.3.2-4 | Award Amount: 3.94M | Year: 2008
The Partners propose to conduct a cohort study in pregnant women and their newborns to quantify the effects of Pregnancy-Associated Malaria (PAM) and to identify a PAM vaccine candidate. Effects of PAM on the pregnant woman (placental infection and anaemia), the offspring (birth weight reduction), and the infant (increased morbidity and mortality) are well known. Studies underlined the role of P. falciparum variable surface antigens expressed on infected erythrocytes in binding to placenta. A specific immune response against this antigen reduces the effect of PAM during latter pregnancies, making possible to develop a new preventive strategy based on the enhancement of this specific response. This goal will be achieved through cohort studies in 2 endemic areas (West and East Africa), as the mechanisms and the resulting effects may vary with transmission. Biological samples will be collected during pregnancy and infancy to dissect the pathological and immune mechanisms involved, as well as to characterize phenotypically and genetically the infecting parasites, providing a structural basis for anti-PAM vaccine design. The immunopathological effects will be measured in the mothers, their newborns, and the infant, in relation with timing of infection. The ultimate goal is to identify the most immunogenic epitopes of VAR2CSA (the major variable surface antigens of P. falciparum parasites infecting the pregnant women) to be included in such a vaccine. It is anticipated that the product of this project will be directly usable to enter in the pipeline of vaccine development. The 7 Partners of the consortium (5 from 4 EU countries, and 2 from Benin and Tanzania) have a combined history of high class, internationally-recognized research in malaria. All EU teams have huge experience of collaboration with malaria endemic countries institutions and with studies related to malaria in pregnant women, that are also routinely conducted by the 2 African Partners.
Agency: European Commission | Branch: FP7 | Program: CP-IP-SICA | Phase: HEALTH-2009-4.3.1-3 | Award Amount: 13.73M | Year: 2010
Worm infections are receiving increased attention due to: the wide geographic overlap in occurrence between worms and HIV, TB and malaria; the large proportion of individuals (minimal estimates around 25%) co-infected with worms and HIV/TB/ malaria; the potential risk of increasing disease burden; the very limited understanding of the impact by worm infections on HIV-, TB- and malaria-specific immune responses and on their clinical outcome; the lack of established intervention guidelines for treatment of worm infections; and the scarce information on the impact by worm infections on vaccination and vaccine-induced immune responses. In order to address these complex and challenging scientific issues, IDEA project will focus its efforts on four primary objectives: a) the worm-induced modulation of the functional and molecular profile of HIV-, TB- and malaria-specific immune responses, b) the impact by worm co-infections on measures of disease activity of PRDs, c) the immunologic markers of worm-, HIV-, TB- and malaria-specific immune responses associated with better control of pathogen replication and disease, and d) the modulation by worm co-infections of vaccine-induced immune responses. To achieve these objectives, IDEA project has developed a global and innovative strategy which includes: a) the alliance between African and European leading scientists in the field of worms, HIV, TB and malaria, b) the multidisciplinary expertise involving immunologists, parasitologists, epidemiologists, clinicians, and experts in vaccines, c) cutting edge immunology and the most innovative technologies to profile immune response, d) the access to large cohort studies bringing a number of centres working on worms and PRDs in Africa together, and e) the access to experimental HIV, TB and malaria vaccine candidates under clinical development in Africa.
INTHEC - Health Education and Community Integration: Evidence based Strategies to increase equity, integration and effectiveness of reproductive health services for poor communities in Sub Saharan Africa.
Agency: European Commission | Branch: FP7 | Program: CP-FP-SICA | Phase: HEALTH-2009-4.3.2-1 | Award Amount: 3.63M | Year: 2010
Objectives: The research aims to improve the delivery of reproductive health (RH) services in Tanzania and Niger by generating new evidence about effective ways to strengthen the provision, uptake, equity and effectiveness of adolescent reproductive health (ARH) programmes. Background: Poor adolescent reproductive health (ARH) continues to be a major cause of morbidity and worsening poverty for the poorest people in sub-Saharan Africa. The effectiveness of ARH programmes implemented within the health and education sectors is seriously hampered by adverse prevailing cultural norms and practices within those sectors and the wider community, and by poor programme integration. Methods: The proposed research will promote equitable reproductive health (RH) service provision and improve its uptake and effectiveness by : (i) conducting a situation analysis of current community and implementer experiences of existing ARH programmes in Tanzania and Niger, identifying priority areas of weakness in RH service provision and opportunities for strengthened service uptake and integration; (ii) addressing identified weaknesses and opportunities by developing an innovative package of interventions in 4 areas: (1) workplace ARH strategy in health units; (2) RH support to teachers in schools; (3) integrated school and community guardian support to pupils; (4) enhanced community referral to health services. We will evaluate the processes and impact of the interventions through a series of rigorous process evaluation studies, which will generate new knowledge, about intervention development, and indicators of intervention processes and effect. The overall impact of the interventions will be evaluated in a population-based cluster randomised trial. Involvement as project partners of the government ministries directly responsible for ARH policy in both Niger and Tanzania, will ensure the policy-relevance of this research, and its continued impact beyond the life of this project.
Agency: European Commission | Branch: FP7 | Program: CP-IP-SICA | Phase: HEALTH.2010.2.3.2-4 | Award Amount: 15.40M | Year: 2011
The AvecNet consortium will develop practical solutions to the current limitations of vector control strategies in Africa using a combination of translationally-aware, state of the art science and end user analysis to ensure successful development and uptake of the new and improved approaches to malaria control and elimination. Our carefully balanced, multidisciplinary team of European and African experts includes vector biologists, engineers, epidemiologists, social scientists and leaders of large supranational consortia. These partners are all prominent members of global vector control research programs having unique specialization in Africa-centric projects. Together we have developed a proposal focused specifically to address the three major research challenges that confront efforts to interrupt mosquito-mediated transmission of malaria in Africa: 1. The need for practical strategies to prolong the efficacy of existing insecticide-based vector control methods, 2.The need to develop new interventions that target all major malaria vectors, that are simultaneously effective, socially acceptable and sustainable, 3. The impact of the major demographic and environmental changes occurring in Africa on malaria epidemiology and control. These research activities are cross-linked by specific tasks to reinforce our commitment to ensure sustainability, engage all stakeholders and strengthen research capacity in Africa. Overall, the project will add significant value to the international research effort in vector control by taking forward the state of the art and translating this into new or improved control tools that will be trialled within the time frame of this project. The studies planned in this collaborative project will provide scalable solutions, giving the solid platform upon which ongoing and future vector control programmes can be built.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-09-2015 | Award Amount: 28.14M | Year: 2016
Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the European HIV Vaccine Alliance (EHVA) program will develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The Specific Objectives of the MVP are to build up: 1.Discovery Platform with the goal of generating novel vaccine candidates inducing potent neutralizing and non-neutralizing antibody responses and T-cell responses, 2. Immune Profiling Platform with the goal of ranking novel and existing (benchmark) vaccine candidates on the basis of the immune profile, 3. Data Management/Integration/Down-Selection Platform, with the goal of providing statistical tools for the analysis and interpretation of complex data and algorithms for the efficient selection of vaccines, and 4. Clinical Trials Platform with the goal of accelerating the clinical development of novel vaccines and the early prediction of vaccine failure. EHVA project has developed a global and innovative strategy which includes: a) the multidisciplinary expertise involving immunologists, virologists, structural biology experts, statisticians and computational scientists and clinicians; b) the most innovative technologies to profile immune response and virus reservoir; c) the access to large cohort studies bringing together top European clinical scientists/centres in the fields of prophylactic and therapeutic vaccines, d) the access to a panel of experimental HIV vaccines under clinical development that will be used as benchmark, and e) the liaison to a number of African leading scientists/programs which will foster the testing of future EHVA vaccines through EDCTP
Agency: European Commission | Branch: FP7 | Program: CSA-CA | Phase: HEALTH.2011.3.4-3 | Award Amount: 2.29M | Year: 2011
Inequalities and vulnerable groups health, as well as the slow advances to achieve the health- related Millennium Development Goals, are concerns that need to be addressed, notably for low and middle-income countries. While some countries have made advances, these remain unknown to other ones which could still benefit from their experience. Higher collaboration could help but is quite difficult to achieve. The MASCOT project gathers therefore 11 partners from 3 geographical areas (Europe, Latin America & Africa), an advisory board and additional relevant experts to answer this problematic. The work is specifically designed to achieve defined objectives: - to create links between North-South and South-South efforts in addressing maternal and child health and health inequalities (MCH&I) in developing countries - to provide evidence on best practice and policy advice for the development of future public health and health systems interventions. Following a first step of standardisation and quality control procedures, the project will implement mapping activities in individual countries of the 3 regions of interest in order to assess the current situation of MCH inequalities, to identify institutions and research teams performing research in this area, to detect promising projects and research results as well as strategies, programs and policies implemented to tackle MCH inequalities. This will result in recommendations of best practices and policy advice to countries willing to implement actions to improve MCH&I. An important part of the work will also stimulate multi-lateral collaboration and knowledge transfer as a key activity of MASCOT. All along the project, different tools such as meetings, workshops, partnering event, website, and brochures will be used to communicate and promote the exchange between health stakeholders and policy-makers. Ultimately MASCOT should thus allow reducing gaps in health inequalities between and within different regions of the world.
News Article | March 2, 2017
Melanie Lee, PhD, est depuis novembre 2014 directrice scientifique de BTG plc, une entreprise de médecine interventionnelle en maladies vasculaires, oncologie et pneumologie. Après sa carrière universitaire, elle a passé dix ans chez Glaxo/GlaxoWellcome (1988-1998). En 1998, Melanie Lee a rejoint Celltech plc en tant que Directeur exécutif chargé de la Recherche. Celltech plc a ensuite été acquise par UCB, dont Melanie Lee a été nommée Vice-Président exécutif, Recherche et Développement. Après avoir quitté UCB en 2009, elle est devenue directrice générale de Syntaxin Ltd, une biotech basée au Royaume-Uni et, à la suite de la vente de l'entreprise à Ipsen, a fondé en 2014 NightstaRx Ltd, une entreprise soutenue par Syncona. Melanie Lee est diplômée en biologie de l'Université de York et titulaire d'un doctorat du National Institute for Medical Research de Londres. Elle a poursuivi des études post-doctorales en génétique moléculaire, tout d'abord sur les levures à l'Imperial College de Londres puis, à partir de 1985, aux côtés du prix Nobel Sir Paul Nurse, aux Lincoln's Inn Laboratories de l'Imperial Cancer Research Fund. Melanie Lee a été élevée en 2009 au grade de commandeur dans l'ordre de l'Empire britannique (CBE) pour service rendu à la science médicale. Bernard Charlès est depuis mai 2016 Vice-président Directeur Général de Dassault Systèmes, leader mondial dans le domaine des logiciels 3D avec plus de 220 000 clients dans 12 secteurs de l'économie. Il était Directeur Général de Dassault Systèmes depuis septembre 1995. Ayant rejoint l'entreprise en 1983, il y crée le département Nouvelles technologies, Recherche et Stratégie et, en 1988, est nommé Directeur Stratégie, Recherche et Développement. Inspirateur des concepts de maquette digitale, gestion de cycle de vie du produit et 3DEXPERIENCE®, Bernard Charlès a contribué à mettre en place une dynamique d'innovation permanente pour asseoir la puissance scientifique de Dassault Systèmes et inscrire la science dans l'identité de l'entreprise. Bernard Charlès est membre de l'Académie des Technologies (France) et de la National Academy of Engineering (Etats-Unis). Ancien élève de l'Ecole Normale Supérieure de Cachan, il est agrégé et docteur en mécanique, spécialisé dans l'ingénierie de l'automatisation et des sciences informatiques. Sanofi, l'un des leaders mondiaux de la santé, s'engage dans la recherche, le développement et la commercialisation de solutions thérapeutiques centrées sur les besoins des patients. Sanofi est organisé en cinq entités globales : Diabète et Cardiovasculaire, Médecine générale et Marchés émergents, Sanofi Genzyme, Sanofi Pasteur et Santé Grand Public. Sanofi est coté à Paris (EURONEXT: SAN) et à New York (NYSE: SNY).
News Article | December 21, 2016
CHICAGO--(BUSINESS WIRE)--Today, Navigant (NYSE: NCI) announced the promotion of 11 professionals to managing director. “We congratulate these leaders, who have served clients with tenacity, integrity, and excellence. By leading with purpose, they have found innovative solutions to complex challenges that make a meaningful impact for our clients,” said Julie Howard, chairman and chief executive officer. “Each of these professionals is recognized for their knowledge, strategic counsel, and leadership in the market. They are an important part of Navigant’s success, and we look forward to their continued contributions.” Byrne has more than 15 years of Navigant experience consulting within the construction sector for a wide variety of client needs. He has extensive experience in delivering large, complex engagements in the oil and gas, power, and heavy civil industries, and has successfully managed project teams on numerous multimillion dollar consulting engagements on multibillion dollar construction projects in the U.S. and international markets. Byrne joined Navigant from the construction industry, where he managed many large, successful projects for both contractors and owners in the heavy civil and petroleum markets. He is regularly involved in our clients’ active construction programs, providing advice and guidance surrounding risk management and mitigation efforts. Farrar joined Navigant in 2008 and he currently advises clients globally on complex issues such as financial accounting investigations, white-collar crime, off-label marketing allegations, Foreign Corrupt Practices Act matters, False Claims Act damage calculations, violations of the Stark Law and the Anti-Kickback Statute, embezzlements, sales and marketing compliance, global transparency laws and regulations, as well as various auditing and monitoring assessments. For the past year, Farrar has been serving as the interim global chief compliance officer for a major medical device and diagnostics company, where he has helped to build the compliance program and establish a global compliance team. Grunfeld is a trusted adviser to senior leaders across the energy sector value chain globally, including utilities, independent power companies, manufacturers, regulators, and governments. Since 2012, Grunfeld has been a leading member of Navigant’s Global Energy segment in Canada, and has worked to grow the Canadian business by over 30 percent annually in each of the past three years. Grunfeld has consulting project experience in the areas of strategy and operations, mergers and acquisitions, project development and finance, regulatory economics, as well as energy market and energy policy design. He is a recognized expert on the energy sector in Canada and has served as an expert witness in regulatory and civil matters. Von Wentzel joined Navigant in 2006 and has nearly 20 years of manufacturing strategy and technical cost modeling experience. Currently, he leads the Energy practice’s efforts in technology testing and evaluation. He directs value engineering studies and manufacturability evaluations to estimate the manufacturing costs of components, products, and systems to determine least-cost design solutions. Von Wentzel is the founder of Navigant’s test facility in Woburn, MA, where his team performs laboratory tests on systems and components used in buildings and industry to support the development of new test methods and performance standards, and to calibrate analytical models of product performance. Wikler has more than 30 years of experience consulting in the energy sector, including the last three years at Navigant. His work has focused on demand-side resources, including energy efficiency, demand response, distributed generation, and smart grid programs for the electric and gas industries. During his career, Wikler has conducted national, regional, and utility-specific market potential studies, technology assessments, program designs, economic assessments, and evaluation studies. His major clients include a number of electric and gas utilities and regulatory agencies throughout North America. In addition, he advises a number of foreign governments on demand-side strategies. Caulfield has more than 15 years of experience in Bank Secrecy Act (BSA) and Anti-Money Laundering (AML) compliance, and has led large teams of professionals in performing monitorships, regulatory compliance gap analysis, and risk assessments of both domestic and foreign financial institutions. He also has helped design AML policies, procedures, and training programs for multiple large financial service companies. Prior to joining Navigant, Caulfield was a director in a Big Four accounting firm, where he provided BSA/AML services to financial institutions, as well as performed forensic accounting reviews and fraud investigations regarding the misappropriation of assets. With 20 years of experience in regulatory compliance, consulting, and law enforcement, McArdle specializes in BSA and AML compliance, fraud prevention, and forensic accounting investigations. McArdle has been selected to act as co-manager of the monitor team chosen by a regulatory agency to oversee a large financial institution. He is specifically tasked with the validation of the institution’s AML transaction-monitoring program and systems, as well as its sanctions program. Additionally, he leads a project on behalf of federal and state prosecutors’ offices ensuring a financial institution adheres to its deferred prosecution agreements. Prior to joining Navigant, McArdle was a senior special investigator for enforcement at the Federal Reserve Bank of New York. Mueller is a member of Navigant’s Global Investigations and Compliance practice. He leads the technology and data analytics team, which focuses on assisting clients with selection, implementation, and review of AML and sanctions screening technology platforms. His team works with clients to: evaluate systems governance; review risk coverage for transaction monitoring detection scenarios and sanctions name-matching algorithms; perform system tuning to maximize effectiveness while minimizing false positives; perform model validation projects for AML and sanctions systems; and support data handling and analytics for large scale file and transaction reviews. Degun has more than 15 years of experience in healthcare and life sciences consulting and R&D. His main areas of focus are R&D and commercial strategy, market access/pricing and reimbursement, real-world data. In addition he focuses on non-interventional studies for major and emerging biological, pharmaceutical, and medical-device companies, government, and the European healthcare sector. His background is in medical research focusing on virology and immunology, and he spent four years at leading medical research institutes and hospitals including the Medical Research Council’s National Institute for Medical Research and the Animal Health and Veterinary Laboratories Agency. Kajogbola is a strategy-focused senior business leader with nearly three decades of experience in healthcare consulting. During his three years with Navigant, he has developed and led large, high-performance organizations to solve complex and strategic challenges across geographic regions. He is adept at providing clear direction and leadership in a changing environment, with a thorough understanding of the healthcare economics and market opportunities. Kajogbola currently plays a leading role in Navigant’s growth by leveraging solutions and collective experience to position the right experts and teams to address strategic and operational challenges for select highly effective provider clients. Smart has more than 20 years of global leadership experience across the healthcare industry gained from management positions in biopharmaceuticals, hospital administration, and strategy consulting. Since 2012, she has been a leading member of Navigant’s Life Sciences practice and has leveraged her clinical background, industry, and provider-side experience to transform Navigant’s market position in the medtech industry. Smart currently supports medical device, diagnostic, and health technology companies by developing innovative market access strategies in both established and emerging markets. She also has extensive experience in advising global medtech and private equity companies in connection with business transactions and commercial due diligence efforts. Navigant Consulting, Inc. (NYSE: NCI) is a specialized, global professional services firm that helps clients take control of their future. Navigant’s professionals apply deep industry knowledge, substantive technical expertise, and an enterprising approach to help clients build, manage, and/or protect their business interests. With a focus on markets and clients facing transformational change and significant regulatory or legal pressures, the firm primarily serves clients in the healthcare, energy, and financial services industries. Across a range of advisory, consulting, outsourcing, and technology/analytics services, Navigant’s practitioners bring sharp insight that pinpoints opportunities and delivers powerful results. More information about Navigant can be found at navigant.com.
News Article | November 30, 2016
When one thinks about chronic conditions that are commonly painful, HIV doesn't typically spring to mind. However, more than 50% of HIV-positive individuals experience a painful condition like headache, chest pain or neuropathy, and that pain is frequently experienced as moderate to severe in intensity. What struck researchers from the Brain Function Research Group (BFRG) at Wits University as odd was that despite this high burden of pain in HIV, a couple of papers have emerged suggesting that, having asked patients, functional interference (having difficulty with things like walking or going to work) was not as great as they might have expected. One of these papers was from the BFRG and had been completed locally in Johannesburg, South Africa. To investigate whether pain does actually affect function in HIV (as it does in many other clinical conditions), researchers Dr Antonia Wadley, Emeritus Professor Duncan Mitchell and Associate Professor Peter Kamerman from the BFRG, based in the School of Physiology, Faculty of Health Sciences at Wits, conducted a cross-sectional study. The results from the study, titled: Resilience does not explain the dissociation between chronic pain and physical activity in South Africans living with HIV, are published today, 13 September 2016, in the journal PeerJ. To explain why pain may not affect function, the researchers first put it down to African patients being resilient, i.e. the ability to cope with adversity. Explains Wadley: "No one has assessed resilience in people living with HIV and chronic pain before. We hypothesised that people living with HIV would be generally be pretty resilient, and those who were more resilient would be more active and report lower pain intensity." Measuring resilience in HIV-patients objectively for the first time For the study, the researchers recruited HIV-positive patients from an HIV clinic in Johannesburg: half with chronic pain (defined as having had pain most days for at least three months) and half without. They then assessed resilience and, as well as asking patients about their activity, the researchers measured it objectively for the first time in a subset of patients using accelerometers, which are like sophisticated pedometers. They also asked the patients about their day-to-day worries. "It turns out," Wadley says, "that we were right on one thing, HIV-positive patients in our study were really resilient, but our hypothesis was wrong: being more resilient did not associate with being more active or having lower pain intensity. In fact, the activity results astounded us. Not only was patients' activity not as affected as one might expect, it wasn't affected at all." There was no difference in activity intensity, duration, or time spent at different intensities of activity between those with and without chronic pain. "This is something you just don't see in other types of long term pain," she adds. The researchers then looked at how frequently patients worried about their health, money, food and family. "We thought that if patients were worried about money and having enough food, that pain might be relegated to a lower priority." They found that patients in chronic pain worried more frequently about each of these things compared to their pain-free counterparts and that health was lowest down the list. "So it really does appear that if you are poor, pain may be relegated to a lower priority. Indeed, our analysis showed that worrying more about food associated with higher levels of activity," says Wadley. The researchers also asked the patients in pain what else they worried about and who they had told about their pain. "It turns out that HIV-related stigma is a real problem and that half the patients in pain had not told their closest friends and some not even their family about their pain, for fear that it might reveal their HIV status." Wadley says it thus seems that economic stresses and fear of HIV-related stigma may drive people to maintain high levels of activity, even when they are in severe pain. "What's not clear is whether this kind level of activity in the face of pain is helpful or harmful and that's something we will be looking into next," she adds. Antonia Wadley is the Hillel Friedland postdoctoral fellow in the School of Physiology, Faculty of Health Sciences, Wits University. Wadley is originally a physiotherapist from the UK but now researches HIV-related pain. She obtained her PhD from Wits University where she looked at clinical and genetic risk factors for developing HIV-associated sensory neuropathy. Her research now focuses on how psychosocial factors affect the experience of pain in HIV. Duncan Mitchell is Emeritus Professor of Physiology in the School of Physiology, Faculty of Health Sciences, Wits University and Honorary Professorial Research Fellow in its Brain Function Research Group. Before joining the Wits in 1975, he was on the faculty of the National Institute for Medical Research, London, UK, and of the Research Organisation of the Chamber of Mines of South Africa, Johannesburg. He is an Honorary Fellow and former President of the Physiology Society of Southern Africa, a member of both the UK and American Physiological Societies, a founder member of the Academy of Science of South Africa, and a Fellow of the Royal Society of South Africa. Duncan has published more than 250 papers, in the fields of thermal physiology, sleep physiology as well as pain physiology and pharmacology. His pain research spans 35 years, and mainly has concerned the pathophysiology and pharmacology of hyperalgesic pain, including muscle pain and dysmenorrhoea. His current pain research is aimed at trying to understand and manage the pain experienced by most HIV-positive patients. He was awarded the Harry Oppenheimer Fellowship in 2010 and an honorary Doctor of Science degree by Wits in 2012. Peter Kamerman is an Associate Professor in the School of Physiology, Faculty of Health Sciences, Wits University and Head of the Pain Laboratory of the Brain Function Research Group. Kamerman's field of research is HIV-related pain with a primary focus on the epidemiology, genetics and pathophysiology of HIV-associated sensory neuropathy. He has published widely in international peer-reviewed journals, and presented numerous invited talks and workshops at local and international conferences. Kamerman is secretary of the Neuropathic Pain Special Interest Group (NeuPSIG) of the International Association for the Study of Pain (IASP) and is president of the Pain Society of South Africa (PainSA). Share the video/Embed the video on your site https:/
News Article | March 2, 2017
Sanofi's Board of Directors Proposes Appointment of Melanie Lee, PhD and Bernard Charlès as New Independent Directors Paris, France - March 2,2017 - At its meeting held on March 2, 2017, the Board of Directors of Sanofi proposed the appointment of Melanie Lee, PhD and Bernard Charlès as new independent Directors during the General Shareholders' meeting of May 10, 2017, as well as the renewal of the term of Fabienne Lecorvaisier. Melanie Lee, PhD, CBE, is Chief Scientific Officer at BTG plc (since November 2014), a company which operates in interventional medicine in vascular disease, oncology and pulmonology. Following her academic career she spent 10 years at Glaxo/GlaxoWellcome (1988-1998). In 1998, Melanie joined Celltech plc as Executive Director of Research. Celltech plc was subsequently acquired by UCB where she became Executive Vice President, Research and Development. After leaving UCB in 2009 she had a successful tenure as CEO at Syntaxin Ltd, a UK based biotech and following the sale to Ipsen, founded NightstaRx Ltd, a Syncona backed company in 2014. Melanie received an undergraduate degree in Biology from the University of York and then a Ph.D. at National Institute for Medical Research in London. She worked as a molecular genetics postdoc, first at Imperial College London on yeast and then from 1985 with Sir Paul Nurse, a Nobel Prize winner, at the Imperial Cancer Research Fund's Lincoln's Inn Laboratories. Melanie received her CBE for services to medical science in 2009. Bernard Charlès has served since May 2016 as Vice-Chairman and Chief Executive Officer of Dassault Systèmes, a world leader in 3D software with over 220,000 customers in 12 industry sectors. He has been CEO of Dassault Systèmes since September 1995. He joined the company in 1983 and created the New Technology, Research and Strategy division, before being appointed Director for Strategy, Research and Development in 1988. Through his contributions to digital mock-up, product lifecycle management and 3DEXPERIENCE®, Bernard Charlès helped instill a culture of ongoing innovation to further consolidate Dassault Systèmes' scientific capabilities and make science part of the company's identity. Bernard Charlès is a member of the Academy of Technology (France) and of the National Academy of Engineering (United States). He is a graduate of the Ecole Normale Supérieure engineering school in Cachan and has a Ph.D. in mechanical engineering majoring in automation engineering and information science. He also holds an Aggregation in mechanical engineering; this is the most senior teaching qualification achievable in France. "Melanie Lee is a renowned scientific expert with a deep knowledge of the pharmaceutical industry and Bernard Charlès has made Dassault Systèmes an international success. They will bring their strengths to further reinforce the capabilities of the Board and contribute significantly to Sanofi's strategy, both in the area of innovation and to the leveraging of opportunities afforded by digital development," said Serge Weinberg, Chairman of the Board, Sanofi. Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).